Advancing Viral Sequencing: Insights from Teresa Cutino Moguel and MGI's Role

Challenges and Obstacles

1. Cost: Sequencing must be cost-effective, especially in the public sector, where it must directly benefit patient care.

2. Expertise: Though there are many intelligent professionals in virology, sequencing remains a niche area. Finding and training the right people can be time-consuming.

3. Data Generation: Engaging clinicians and lab workers in using this technology and providing essential metadata for interpreting sequencing data can be challenging.

The Role of Women in Science

Teresa emphasizes that everyone, regardless of gender or resources, has the potential to contribute to science. She also highlights the importance of role models for younger women, stressing the need for representation in the field.

Projects and Collaborations

Teresa's team is working on various projects, focusing on developing and growing sequencing capability for diagnostic purposes and understanding pathology. Collaborations have been made possible thanks to the pandemic, allowing connections with colleagues in universities and other areas.

Accessibility of Technology

The technology that brings knowledge and benefits to everyone must be accessible to all. Teresa stresses the need for this technology to reach all corners of the world, allowing contributions from capable and motivated individuals everywhere.

Conclusion

Teresa Cutino Moguel's testimony provides valuable insights into the world of viral sequencing and the role of technology in advancing this field. Her emphasis on accessibility, representation, and collaboration paints a picture of a future where science is inclusive and reaches every part of the globe. Her work with MGI-Tech equipment showcases the potential of modern technology in transforming healthcare and research.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.